HONG KONG – Japan's Hitachi Chemical Co. Ltd. plans to acquire the entire share float of Apceth Biopharma GmbH, a contract manufacturing organization (CMO), spending about €75.5 million or ¥9.4 billion (US$85.2 million) on the German company's stock.
HONG KONG – Japan's Hitachi Chemical Co. Ltd. plans to acquire the entire share float of Apceth Biopharma GmbH, a contract manufacturing organization (CMO), spending about €75.5 million or ¥9.4 billion (US$85.2 million) on the German company's stock.
HONG KONG – China's Ascletis Pharma Inc. and California-based 3-V Biosciences Inc. have inked a licensing deal for 3-V Biosciences' fatty acid synthase (FASN) inhibitor TVB-2640.
HONG KONG – Shenyang, China-based 3Sbio Inc. has signed a partnership agreement with Verseau Therapeutics Inc., of Lexington, Mass., to develop and commercialize monoclonal antibodies in the field of immuno-oncology for a broad range of cancers. The collaboration will be based on Verseau's drug discovery platform, which generates first-in-class macrophage checkpoint modulators (MCMs) to treat patients with cancer, immune and inflammatory diseases.
HONG KONG – China's Ascletis Pharma Inc. and California-based 3-V Biosciences Inc. have inked a licensing deal for 3-V Biosciences' fatty acid synthase (FASN) inhibitor TVB-2640.
HONG KONG – Shenyang, China-based 3Sbio Inc. has signed a partnership agreement with Verseau Therapeutics Inc., of Lexington, Mass., to develop and commercialize monoclonal antibodies in the field of immuno-oncology for a broad range of cancers. The collaboration will be based on Verseau's drug discovery platform, which generates first-in-class macrophage checkpoint modulators (MCMs) to treat patients with cancer, immune and inflammatory diseases.
HONG KONG – Samsung Bioepis Co. Ltd. has inked a deal for the mainland China market with investment firm C-Bridge Capital Partners LLC, which will generate a new company: Affamed Therapeutics. The licensing agreement covers multiple biosimilar candidates from Samsung Bioepis. This includes its third-wave biosimilars SB-11 and SB-12, which are ranibizumab and eculizumab candidates based on Genentech Inc.'s Lucentis and Alexion Pharmaceuticals Inc.'s Soliris, respectively.
